EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 484 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July June 25, 2025 World Cancer Day 2023: where does the UK stand? February 3, 2023 Cancer Control in American Indian and Alaska Native Populations: A Conversation... April 25, 2018 Seeing a Promising Future for Progress against Childhood Cancer September 16, 2021 Load more HOT NEWS Educators Raise Money in Memory of Teacher Who Dedicated Herself to... Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... ESMO World Congress on Gastrointestinal Cancer 2022 Barcelona, Spain 29 June... Five Questions With…Desiree.
